Literature DB >> 34221836

A case of raised CA 19-9 in a patient with desmoplastic fibroblastoma of the upper limb.

Kumaran Rasappan1, Leanne Kayla Rebecca Mei-Yi Shaw2, Lester Wai Mon Chan1, Khoon Leong Chuah3, Mathew Hern Wang Cheng1.   

Abstract

Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker widely accepted as the most useful blood test in diagnosing and monitoring pancreatic cancer. However, CA 19-9 may also be raised in other conditions such as colorectal, hepatic, lung, and ovarian carcinoma as well as benign conditions such as hepatobiliary and pulmonary diseases. CA 19-9 is rarely elevated above 200 U/ml in benign conditions with values exceeding 1000 U/ml being highly suggestive of malignancy. The mechanism of secretion in both malignant and benign conditions remains unclear. Desmoplastic fibroblastoma (DF) is a benign soft tissue tumor. CA 19-9 has not been reported in association with DF previously. We present a case of raised serum CA 19-9 in a 71-year-old male attributed solely to DF in his left cubital fossa. The patient's CA 19-9 level rose from 56 U/ml at the time of presentation to 3763.8 U/ml over a period of 9 months. Post-DF excision, the CA 19-9 level decreased to 1464 U/ml at 1 month, 162.3 U/ml at 2.5 months, and 24U/ml, within normal range, at 7 months post-surgery. CA 19-9 levels continued to remain at 24 U/ml 1.5 years post-tumor excision. The CA 19-9 level in this patient was highly elevated which is unusual in association with a benign tumor. The rate of decrease in CA 19-9 level post-excision was in keeping with that reported after pancreatic cancer resections. This is the first case of DF in association with raised CA 19-9. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Benign soft tissue tumor; Biochemistry; CA 19–9; Desmoplastic fibroblastoma; Tumor markers

Year:  2021        PMID: 34221836      PMCID: PMC8206393          DOI: 10.1007/s13691-021-00485-z

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  24 in total

1.  Increased serum CA 19-9 antibodies in Sjögren's syndrome.

Authors:  R Safadi; M Ligumsky; E Goldin; Y Ilan; Y S Haviv; S Nusair
Journal:  Postgrad Med J       Date:  1998-09       Impact factor: 2.401

Review 2.  CA 19-9 in pancreatic cancer.

Authors:  R E Ritts; H A Pitt
Journal:  Surg Oncol Clin N Am       Date:  1998-01       Impact factor: 3.495

3.  Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.

Authors:  S Pearce; H Thornes; D Carr; A Tanner
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

4.  The clinical significance of elevated levels of serum CA 19-9.

Authors:  S Pavai; S F Yap
Journal:  Med J Malaysia       Date:  2003-12

5.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

6.  Persistent elevation of serum CA 19-9 with no evidence of malignant disease.

Authors:  M Ventrucci; P Pozzato; A Cipolla; G Uomo
Journal:  Dig Liver Dis       Date:  2008-07-03       Impact factor: 4.088

7.  CA 19-9 expression in subacute (de Quervain's) thyroiditis: an immunohistochemical study.

Authors:  K W Schmid; C Ofner; T Ramsauer; A Hittmair; M Tötsch; D Ladurner; W Böcker
Journal:  Mod Pathol       Date:  1992-05       Impact factor: 7.842

8.  Disappearance curves for tumor markers after resection of intrathoracic malignancies.

Authors:  T Yoshimasu; S Maebeya; T Suzuma; T Bessho; H Tanino; J Arimoto; T Sakurai; Y Naito
Journal:  Int J Biol Markers       Date:  1999 Apr-Jun       Impact factor: 3.248

Review 9.  Classic tumor markers in gastric cancer. Current standards and limitations.

Authors:  Călin Căinap; Viorica Nagy; Alexandra Gherman; Sanziana Cetean; Istvan Laszlo; Anne-Marie Constantin; Simona Căinap
Journal:  Clujul Med       Date:  2015-04-15

10.  Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases.

Authors:  Sunyoung Kim; Byung Kyu Park; Jeong Hun Seo; Jinyoung Choi; Jong Won Choi; Chun Kyon Lee; Jae Bock Chung; Yongjung Park; Dong Wook Kim
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.379

View more
  1 in total

1.  Diagnostic biomarkers for pancreatic cancer: An update.

Authors:  Ming Yang; Chun-Ye Zhang
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.